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Background: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in hospitalised patients.
VTE prevention has been identified as a major health need internationally to improve patient safety. A National
Institute for Health and Clinical Excellence (NICE) guideline was issued in February 2010. Its key priorities were to
assess patients for risk of VTE on admission to hospital, assess patients for bleeding risk and evaluate the risks and
benefits of prescribing VTE prophylaxis.
The aim of this study was to evaluate the implementation of NICE guidance and its impact on patient safety.
Methods: A before-after observational design was used to investigate changes in VTE risk assessment
documentation and inappropriate prescribing of prophylaxis between the year prior to (2009) and the year
following (2010) the implementation of NICE guidance, using data from a 3-week period during each year. A total
of 408 patients were sampled in each year across four hospitals in the NHS South region.
Results: Implementation strategies such as audit, education and training were used. The percentage of patients for
whom a VTE risk assessment was documented increased from 51.5% (210/408) in 2009 to 79.2% (323/408) in 2010;
difference 27.7% (95% CI: 21.4% to 33.9%; p < 0.001). There was little evidence of change in the percentage who
were prescribed prophylaxis amongst patients without a risk assessment (71.7% (142/198) in 2009 and 68.2%
(58/85) in 2010; difference −3.5% (95% CI: -15.2% to 8.2%; p =0.56) nor the percentage who were prescribed low
molecular weight heparin amongst patients with a contraindication (14% (4/28) in 2009 and 15% (6/41) in 2010;
RD = 0.3% (95% CI: -16.5% to 17.2%; p =0.97).
Conclusions: The documentation of risk assessment improved following the implementation of NICE guidance; it is
questionable, however, whether this led to improved patient safety with respect to prescribing appropriate
prophylaxis.
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Venous thromboembolism (VTE) is a major, and often
unrecognised cause of patient morbidity and mortality
in hospitalised patients [1]. Pulmonary embolism (PE)
accounts for 5-10% of hospital deaths and is, therefore,
often quoted as the most preventable cause of death in
hospital [1-5]. Hospitalised patients are at a 100 times
greater risk than primary care patients [6] and between
25-30% of non-fatal VTEs occur in patients with prior
hospitalisation [1].
The prevention of VTE has been identified as a major
health need nationally and internationally to improve pa-
tient safety [5]. A recent multinational, observational,
cross-sectional study carried out in 358 hospitals from 32
different countries (the ENDORSE study) showed that
51.8% of patients were at risk of VTE and only 50.2% of
patients who were deemed to be at risk received prophy-
laxis [4]. A retrospective review of patients with a diag-
nosis of VTE was performed in 2010 in New Zealand
and supported these findings. It demonstrated that 25%
of patients with a VTE had been admitted to hospital in
the preceding three months. Of these patients, two thirds
had not received appropriate prophylaxis [7].
Several trials have been performed studying the use of
single and multiple implementation strategies [5,8-10].
Single strategies such as passive dissemination are
the least effective method of implementing guidelines,
whereas combined systems of education, reminders,
audit and feedback are believed more effective [5]. Many
studies, however, presented short term data, so it is not
known whether these implementation programmes had
lasting effects [5,8]. In addition, many are examining the
implementation of local guidelines.
This study presents data from the implementation of a
new national guideline issued by the National Institute
for Health and Clinical Excellence (NICE) in the UK in
February 2010 (see below) [11].
NICE Clinical Guideline 92, 2010 [12]
Key priorities:
 Assess patients for risk of VTE on admission to
hospital
 Assess patients for bleeding risk
 Weigh up benefits and risks of prescribing
prophylaxis and prescribe if appropriate
Prophylactic measures to be taken if indicated:
 Pharmacological measures, e.g., fondaparinux
sodium, LMWH, unfractionated heparin (UFH) in
patients with renal failure
 Mechanical prophylaxis, e.g., anti-embolism
stockings, foot impulse devices and intermittent
pneumatic compression devicesGeneral measures should also be taken:
 Early mobilisation
 Adequate hydration
Objectives
The aim of this study was to evaluate the implementa-
tion of the NICE guideline across four hospitals in the
NHS South of England region, and its impact on patient
safety using the following outcome measures:
1. The percentage of patients for whom a risk
assessment was documented.
2. The percentage of patients who received VTE
prophylaxis amongst those who were not risk assessed.
3. The percentage of patients who received VTE
prophylaxis amongst those with a contraindication
to VTE prophylaxis.
The percentages were compared between the years
prior to (2009) and following (2010) publication of the
NICE guideline.
Methods
Study method
A before-after observational study design was used to
evaluate the implementation of the NICE guideline on
VTE prevention in four hospital sites. Two specialties
were covered in this study; one with a relatively high
proportion of elective patients (orthopaedics) and one
with a high proportion of emergency admissions (gen-
eral internal medicine).
Sample selection
We sampled four hospitals to provide a maximum-
variety sample of initially divergent models of VTE pre-
vention activity because that would be likely to expose a
range of approaches to implementing the NICE guide-
line, and a wide range of staff attitudes and motives. Our
sampling frame was a regional census which reported
current practice, the organisational context and VTE
prevention activity for each hospital.
Each hospital approached the request to devise a sam-
pling frame in different ways. Hospital A gave free access
to admission data, however, Hospitals B, C and D would
not release admission data but did provide a file sample
of patient files for audit. Subsequent data analysis con-
firmed that in those hospitals where it was not possible
to take our own sample, a random cross-section of files
had been made available without ‘cherry-picking’ files to
show 100% compliance with national VTE risk assess-
ment guidelines.
The sample was systematically drawn from a list of all
adult admissions of over 24 hours for a three-week
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year following (2010) the NICE guideline publication.
Data from 2009 were extracted as these pre-date proto-
col implementation, whilst 2010 data were used to cover
the post-guidance implementation phase. October was
chosen to minimise the impact of the four-monthly rota-
tion of junior doctors and the seasonal inflow of tourists.
Fifty one orthopaedic patient records and 51 general
medicine patient records were sampled from each site in
each of 2009 and 2010 (408 subjects overall in each year).
This sample size is large enough to detect an increase
from 50% in 2009 to 60% in 2010 in the proportion of pa-
tients for whom a risk assessment was documented, with
80% power at the 5% level of significance.
Hospital characteristics
Table 1.
Hospitals with Exemplar Status
Hospitals are given ‘Exemplar Status’ in the UK if they
can show an existing track record of excellent VTE pre-
vention and care. Hospitals are invited to join the ‘Exem-
plar Centre Network’ where they are able to share
examples of good practice such as clinical best practice
and educational and audit material, provide advice regard-
ing VTE care, receive visitors and collaborate on clinical
research into VTE. The network can also provide help and
advice in relation to managing VTE prevention locally
such as establishing hospital thrombosis committees [13].
Hospital A was awarded Exemplar Status in December
2009, recognising the extensive work it had completed
towards good clinical care in the prevention of VTE. The
Thrombosis Committee within this hospital was established
in March 2006. The Trust demonstrated their commitment
to VTE prevention in 2010, by putting in place a VTE
prevention team, including a full time VTE Clinical Nurse
Specialist, some designated senior doctor clinical time and
audit/pharmacy time.
Hospital D was also awarded Exemplar status in
December 2009. It developed a simple means of
documenting VTE risk with a ‘risk box’ on the front of the
drug chart together with a recommendation for prophylaxis
and space to document any contraindications toTable 1 Hospital characteristics
Hospital site A B C D
Population 500,000 450,000 350,000 200,000
Staff 6,000 5,200 6,000 3,900
Beds 940 750 850 550
Teaching Hospital Yes Yes Yes No
Foundation status No No Yes Yes
Exemplar Status prior to NICE
guidance
Yes No No Yesprophylaxis or reassessment of risk in early 2008. Risk deci-
sions and prophylaxis were facilitated by a simple algo-
rithm, which ensured that a high proportion of patients
admitted to the Trust, would receive appropriate
individualised measures to minimise their risk of VTE.
Any VTE event was reviewed by the thrombosis com-
mittee and information fed back to the relevant clinical
teams so that they had a better understanding of their
own performance based on clinical outcomes.
Data collection
Data on risk assessment, diagnosis and method of
prophylaxis were extracted by a data collection instru-
ment; designed mainly for ‘tick-box’ entry of standard
data entry fields. Two experienced researchers reviewed
the medical records, both of whom received training on
reading medical records from a qualified practitioner be-
fore starting the data extraction. Qualitative data were
collected from key informants at various levels of the
medical and management hierarchies. Forty-four semi-
structured interviews were completed with 50 inter-
viewees across the four sites over an 18 month period
during 2010 and 2011. The interviews described the pre-
NICE 2009 systems and reported how each hospital had
responded to the 2010 NICE guidance and what factors
appeared to facilitate or hinder compliance.
Analysis
The Chi-squared test was used to compare the following
binary outcomes between 2009 and 2010: (1) whether pa-
tients had a documented risk assessment, (2) whether pa-
tients who were not risk assessed received VTE
prophylaxis regardless, and (3) whether patients with a
contraindication to VTE prophylaxis received it. The per-
centages with these traits are reported for each year, both
overall and within each site, and the 95% confidence inter-
val for the overall change in percentage. Tests of inter-
action were used to quantify evidence of differential
change across the four sites. Statistical analyses were car-
ried out using Stata software.
For the qualitative assessments, a semi-structured inter-
view schedule was used starting with junior medical staff
and working up the medical and managerial hierarchies.
Ethical approval
Ethical approval was not needed for this study as it was
deemed a service evaluation by the local NHS Research
and Development Service.
Results
Risk assessment and prophylaxis prescribing
There was strong evidence of an increase in the percent-
age of patients for whom a risk assessment for VTE
prophylaxis was documented after implementation of
Table 2 Risk assessment, prophylaxis use and low-
molecular weight heparin use by hospital in 2009 and
2010
Hospital Year Risk assessment,% Prophylaxis
use,%
LMWH
use,%
All 2009 51.5 80.4 49.8
2010 79.2 85.8 60.3
A 2009 43.1 91.2 67.6
2010 90.2 97.1 60.8
B 2009 58.8 76.5 63.7
2010 83.3 82.4 52.9
C 2009 32.4 71.6 24.5
2010 67.6 79.4 67.6
D 2009 71.6 82.4 43.1
2010 75.5 84.3 59.8
*sample size is 102 for each hospital and year.
Data in each year collected over a 3-week period.
LMWH: low-molecular weight heparin.
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27.7%; 95% CI: 21.4% to 33.9%; p < 0.001) (Table 2). Risk
assessment documentation increased in all four hospi-
tals, although a test of interaction indicated that the
amount of change differed among them (p < 0.001).
The percentage of patients receiving any form of
prophylaxis is also shown in Table 2. Again, there was
evidence at the 5% level of an improvement overall
(absolute increase across all sites = 5.4%; 95% CI: 2.6% to
10.5%; p = 0.04), with each hospital showing an improve-
ment. Although the use of low molecular weight heparin
(LMWH) increased overall (absolute increase across all
sites = 10.5%; 95% CI: 3.8% to 17.3%; p = 0.002), it
decreased in hospitals A and B; a test of interaction indi-
cated evidence that the amount of change differed across
the hospitals (p < 0.001).0
5
10
15
20
25
*Cerebrovascular event, e.g. strok
**Do not attempt resus
Figure 1 Documented reasons for contraindications to VTE prophylaxContraindications and documented risk assessment
The number of patients who were not risk assessed de-
creased. However, the percentage of patients who re-
ceived prophylaxis without documentation of a risk
assessment only decreased slightly from 71.7% (142/198)
to 68.2% (58/85) and there was little evidence of a true
change (absolute decrease = 3.5%; 95% CI: -8.2% to
15.2%; p = 0.56). The percentage of patients who re-
ceived LMWH when a contraindication was present was
unchanged (14% (4/28) in 2009 versus 15% (6/41) in
2010; RD = 0.3%; 95% CI: -16.5% to 17.2%; p =0.97).
We also examined the different contraindications doc-
umented. Sixty nine of the 816 patients (8.5%) were doc-
umented to have a contraindication to VTE prophylaxis
in total. Of these, the three main reasons given were: 1)
taking warfarin concomitantly (n = 19, 28%), 2) at risk of
bleeding (n = 18, 26%), and 3) possible cerebrovascular
event (n = 10, 14%). A few questionable reasons were
also given, such as ‘needle phobic’ (n = 1, 1%) or ‘at risk
of falls’ (n = 1, 1%) (see Figure 1). In 33% of cases
(n = 23) no reason for contraindication was documented.Implementation strategies
The interviews with hospital professionals were tran-
scribed and analysed using thematic content analysis.
Findings demonstrated that the NICE guideline ensured
a more systematic approach to VTE risk assessment and
prescribing of prophylaxis in all four hospitals studied.Policy and leadership
All hospitals included in this study had local policies
prior to implementation of the NICE guideline and
adapted their protocols to include the NICE recommen-
dations, including clearly defined roles and respon-
sibilities for staff. For example, Hospital A favourede/transient ischaemic attack
citation order
is.
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patients received prophylaxis unless contraindicated.
Hospital B used multiple guidelines for VTE prevention,
where each department had its own protocol. Hospital
C emphasised early risk assessment with selective pre-
scribing of prophylaxis, where only patients with a clear
clinical need for prophylaxis received any. This probably
explains the low percentage of prophylaxis prescribing
in that hospital.
All hospitals created dedicated multi-disciplinary VTE
committees with the consultants and clinical managers
as champions:
‘The VTE committee is quite robust and it has then
sparked interest and support from the Trust Board,
which has been really the key, and I think Dr N, a
lead haematologist has been given an actual
recognised role that’s also, you know, properly sort of
remunerated, and securing a post for a VTE nurse has
also been a key thing’ (Consultant, Hospital A).
Hospital D also included patients in the VTE commit-
tee in order to gain an additional perspective.
Risk assessment
The NICE guideline stipulated that all risk assessments
were to be documented and all patients were to receive
appropriate prophylaxis. NICE recommended that the
tools were clear, easy to use and incorporated into an-
other document to aid compliance. All sites incorpo-
rated the risk assessment into the drug charts used
throughout the hospital. For example:
‘In terms of the risk assessment that takes place when
every patient is, or it should take place when every
patient is admitted, because every drug chart in the
hospital has a risk assessment box on it that inevitably
has to be performed by the junior doctor on admission’
(Pharmacist, Hospital B).
Measurement and audit
All hospitals in our study conducted regular audits to
measure compliance with risk assessment and presented
results to the hospital staff at local meetings. Inter-
viewees also commented on the importance of monitor-
ing the link between risk assessments and prescribing
appropriate prophylaxis:
‘Our VTE risk assessment audit picks up on that
because we look at how many patients have been
prescribed Dalteparin and based on the fact that they
have been categorised as being high risk, I would say
we are running at about 97% prescribed Dalteparin.
The patients who have not been prescribed Dalteparinnormally have a documented reason why they have
not received it’ (Pharmacist, Hospital D).
Some hospitals also conducted ward-based audits,
which ensured transparency of results throughout the
specialities and hospitals promoting awareness and edu-
cation about VTE.
Staff education and training
Hospitals A, C and D created a ‘link’ role, in the form of
a VTE specialist nurse with a role in education and com-
munication between medical, nursing and managerial
staff. Hospital B is currently looking into employing a
lead nurse.
Training in VTE risk and prophylaxis was included in
the staff/trust induction of all hospitals. Hospital B made
the completion of an online learning package regarding
VTE risk mandatory within 48 hours of joining the trust.
This trust also endorsed the use of an electronic white-
board or ‘smartboard’, which obliged junior doctors to fill
in the risk assessment for VTE, making it easier for con-
sultants to see which patients had or had not been risk
assessed for VTE prophylaxis. Hospital C developed a
series of educational interventions and consultations
across the Trust:
‘There are a large number of training trackers, and
each group will have mandatory ones to take;
mandatory training trackers… There have been
seminars, we moved from Tinzaparin to a single low
molecular heparin in this trust and we have a road
show and seminars for people and an education
process around that, so those seminars have happened.
We have our audit meetings where things get
presented out and so we have audit days which
includes talking about VTE’ (Consultant, Hospital C).
Hospital D adopted a multimedia approach to educate
and remind staff about VTE prophylaxis, e.g., screen
savers, posters, printed leaflets in payslips etc.
Discussion
Main findings
All four hospitals showed a commitment to reduce avoid-
able VTEs and associated deaths. Our results show an im-
provement in the percentage of patients who are risk
assessed for VTE across all hospitals. Hospital C, which
showed the greatest increase, had no formal method of re-
cording prophylaxis use and risk assessment before NICE
guideline implementation. The hospital that showed the
least improvement (hospital D), had exemplar status be-
fore the publication of the NICE guideline and already had
high levels of risk assessment prior to it. The other exem-
plar site (hospital A) showed a dramatic improvement in
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the NICE guideline. This hospital (hospital A) previously
had an ‘opt-out’ system; every patient received prophylaxis
unless a contraindication was present. Clinicians did not
formally record the risk assessment, hence relatively low
levels were recorded in 2009. In 2010 it was the best site
for recording risk assessment.
Patient safety
We used the measures ‘the percentage of patients who
received VTE prophylaxis amongst those who were not
risk assessed’ and ‘the percentage of patients who re-
ceived VTE prophylaxis amongst those with a contra-
indication to VTE prophylaxis’ to assess patient safety as
prescribing in this group can potentially have cata-
strophic consequences for the patient. There was little
evidence of a reduction in the percentage of patients
prescribed prophylaxis who had not been risk assessed
or for whom prophylaxis was contraindicated. The NICE
guideline therefore did not appear to have an impact
on the safety of these patients, although the large
confidence interval widths indicate palpable uncertainty
about the true change in inappropriate prophylaxis use.
Strengths of the study
We were able to use the dissemination of a national
guideline to evaluate implementation strategies across
four diverse hospital sites, which made a before-after ob-
servational study the strongest practicable study design
for answering our research questions.
Limitations of the study
We chose the outcomes for this study to show if the
guideline had improved patient safety. We acknowledge
that there are other outcomes, which could also show
this, such as ‘VTE attributable death’, but it was not pos-
sible to record this information.
Although before-after observational study was the best
design, we recognise that it is not of as high methodo-
logical rigour as a randomised controlled trial and does
not control for secular changes that may have occurred
in the absence of guideline introduction.
Although recording bias is a possibility we would sug-
gest that this is unlikely. The researchers used a standard
data extraction sheet for all data recording and data
were lifted from medical records and recorded word for
word.
We were only able to present short term post-imple-
mentation data (i.e., 8 months after the implementation
of the NICE guideline) and therefore do not know if
these changes can be sustained or indeed improved in
the long term.
The VTE risk of the patient populations may have
been marginally different between 2009 and 2010. Thisshould not have an impact on the percentage of patients
that were risk assessed, however, as every patient, re-
gardless of VTE, should have been risk assessed in line
with the NICE guideline.
Finally, the study was conducted across only four hos-
pitals and this is too small a sample from which to gen-
eralise the findings to the full spectrum of hospitals in
England.
Conclusions
National guidelines are effective at ensuring that hospitals
promote evidence-based practice. The NICE guideline
‘Venous thromboembolism - reducing the risk’ was imple-
mented by all the hospitals in our study sample and more
patients were risk assessed and prescribed prophylaxis fol-
lowing the introduction of the guideline. It is questionable,
however, if this improved patient safety with regard to the
‘high risk’ patients (i.e. in those without a risk assessment
or in those with a contraindication).
A multifaceted approach seems essential to continue
the implementation and to ensure that all hospitals
maintain and improve risk assessment rates. More im-
portantly, there needs to be a shift of focus from risk as-
sessment documentation to appropriate prescribing of
prophylaxis which is the aim of the NICE guideline.
Competing interests
All authors declared that they have no competing interests.
Authors’ contributions
CG and RS conceived the study. AC and TN participated in design and the
coordination of the study. SC and OB were responsible for data collection.
OU performed the statistical analysis. AB drafted the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This article presents independent research funded by the National Institute
for Health Research (NIHR) Collaboration for Leadership in Applied Health
Research and Care (CLAHRC) for the South West of England. The views
expressed in this publication are those of the author(s) and not necessarily
those of the NHS, the NIHR or the Department of Health.
Funding
National Institute for Health Research (NIHR)
What is already known on the topic
 Multiple implementation strategies can improve guideline adherence
 Raising awareness through audit and education are especially
effective methods of implementation of guidelines.
 Implementation strategies can be difficult to maintain in the long-term.
What this study adds
 Documentation of risk assessment for VTE has improved within a
relatively short period following the implementation of NICE
guidance.
 Prophylaxis use in the presence of a contraindication has not reduced
despite NICE guidance and therefore it can be argued that patient
safety has not improved.
 Education needs to continue to include the importance of
documenting contraindications to VTE prophylaxis.
Bateman et al. BMC Health Services Research 2013, 13:203 Page 7 of 7
http://www.biomedcentral.com/1472-6963/13/203Author details
1PenCLAHRC, National Institute for Health Research, Plymouth University
Peninsula Schools of Medicine and Dentistry, N6 ITTC Building, Tamar
Science Park, Derriford, Plymouth PL6 8BX, UK. 2PenCLAHRC, National
Institute for Health Research, Exeter Medical School, Exeter, UK. 3Plymouth
Hospitals NHS Trust, Universities of Plymouth, Plymouth, UK. 4Wesley
Research Institute, University of Queensland School of Population Health,
Queensland University of Technology School of Public Health, Brisbane,
Australia.
Received: 6 July 2012 Accepted: 1 June 2013
Published: 4 June 2013
References
1. Douketis JD, Moinuddin I: Prophylaxis against venous thromboembolism
in hospitalized medical patients: an evidence-based and practical
approach. Pol Arch Med Wewn 2008, 118(4):209–215.
2. Rashid ST, et al: Venous thromboprophylaxis in UK medical inpatients.
J R Soc Med 2005, 98(11):507–512.
3. Maynard G, Stein J: Designing and implementing effective venous
thromboembolism prevention protocols: lessons from collaborative
efforts. J Thromb Thrombolysis 2010, 29(2):159–166.
4. Cohen AT, et al: Venous thromboembolism risk and prophylaxis in
the acute hospital care setting (ENDORSE study): a multinational
cross-sectional study. Lancet 2008, 371(9610):387–394.
5. Gibbs H, et al: Venous thromboembolism prophylaxis guideline
implementation is improved by nurse directed feedback and audit.
Thromb J 2011, 9(1):7.
6. Gallagher M, Oliver K, Hurwitz M: Improving the use of venous
thromboembolism prophylaxis in an Australian teaching hospital.
Qual Saf Health Care 2009, 18(5):408–412.
7. Wiseman DN, Harrison J: A retrospective review of the use of
thromboprophylaxis in patients who subsequently developed a venous
thromboembolism after discharge from hospital. N Z Med J 2010,
123(1309):37–49.
8. Mosen D: The Effect of a Computerized Reminder System on the
Prevention of Postoperative Venous Thromboembolism < xref rid =
"AFF1‘ ><sup > *</sup ></xref>. CHEST Journal 2004, 125(5):1635.
9. Sobieraj DM: Development and implementation of a program to assess
medical patients’ need for venous thromboembolism prophylaxis.
Am J Health Syst Pharm 2008, 65(18):1755–1760.
10. Clark BM, et al: Effective quality improvement of thromboprophylaxis in
acute medicine. BMJ Qual Saf 2011, 20(5):460–464.
11. NICE (Ed): NICE, Venous thromboembolism - reducing the risk; 2010.
12. NICE, Venous thromboembolism - reducing the risk. NICE; 2010.
13. A.-P.P.T. Group (Ed): Health, D.o., Venous Thromboembolism Prevention A
Patient Safety Priority. London:40.
doi:10.1186/1472-6963-13-203
Cite this article as: Bateman et al.: The implementation of nice guidance
on venous thromboembolism risk assessment and prophylaxis: a
before-after observational study to assess the impact on patient safety
across four hospitals in England. BMC Health Services Research 2013
13:203.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
